MedTrace Logo

Study of CVN424 in Parkinson's Disease Patients With Motor Fluctuations

NCT04191577 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 136

Last updated 2024-07-03

Study results available
· View outcomes & findings →

Summary

This is a phase 2 study, randomized, double-blind, placebo-controlled, multicenter study of oral CVN424 at two dose levels (low-dose and high-dose) in Parkinson's disease (PD) patients with motor fluctuations.

Conditions

  • Parkinson Disease

Interventions

DRUG

CVN424 Low Dose

CVN424

DRUG

CVN424 High Dose

CVN424

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Cerevance Beta, Inc.

    lead INDUSTRY

Principal Investigators

  • Susan Kapurch · Cerevance, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-02
Primary Completion
2021-11-06
Completion
2021-12-13
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04191577 on ClinicalTrials.gov